IP Verse

Tablet Formulation Comprising A Peptide And A Delivery Agent - EP2863895

PATENT ANALYSIS

Patent Details

Grant Date
Apr 14, 2021
Company
NOVO NORDISK A/S
Oppositions

CMS CAMERON MCKENNA NABARRO OLSWANG LLP

GALENICUM HEALTH S.L.U.

GENERICS [UK] LIMITED

KRKA, D.D., NOVO MESTO

MERCK SHARP & DOHME CORP.

SANDOZ AG

TEVA PHARMACEUTICAL INDUSTRIES, LTD.

More patents of Novo Nordisk A/S

EP3488857

EP3542790

EP3746111

Want to monitor this patent?

Feel free to send us a message here and we will get back to you